期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 15, 期 11, 页码 1427-1440出版社
TAYLOR & FRANCIS AS
DOI: 10.1586/14737159.2015.1094379
关键词
epidermal growth factor receptor; liquid biopsy; lung cancer; saliva; target therapy
类别
资金
- Ministry of Health and Welfare, Taiwan [MOHW104-TDU-B-211-124-003, MOHW104-TDU-B-211-113002]
- Ministry of Science and Technology, Taiwan [MOST103-2120-M-006-002, MOST103-2314-B-006-064]
- PHS grant [U01 DE015018, U01 DE017790]
Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据